Cargando…

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

BACKGROUND: Hyperphosphataemia is a common complication of chronic kidney disease (CKD). PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders. METHODS: In this double-blind, parallel-group, place...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampson, Mark, Faria, Nuno, Powell, Jonathan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311578/ https://www.ncbi.nlm.nih.gov/pubmed/32651955 http://dx.doi.org/10.1093/ndt/gfaa116

Ejemplares similares

Severe hypocalcaemia and hyperphosphataemia caused by oral sodium phosphate fleet solution in a haemodialysis patient after parathyroidectomy
por: Mok, Maggie Ming Yee, et al.
Publicado: (2011)

Symptomatic Hyperphosphataemia Following Phosphate Enema in A Healthy Adult
por: Carl, Ian, et al.
Publicado: (2007)

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
por: Negri, Armando Luis, et al.
Publicado: (2015)

Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial
por: Ketteler, Markus, et al.
Publicado: (2022)

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions
por: Ketteler, Markus, et al.
Publicado: (2013)

Phosphate reabsorption in the kidney: NaPi-IIb or not IIb
por: Burns, David, et al.
Publicado: (2020)

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
por: Plagemann, Thomas, et al.
Publicado: (2011)

Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis
por: Thet, Zaw, et al.
Publicado: (2013)

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study
por: Locatelli, Francesco, et al.
Publicado: (2014)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
por: Thiem, Ursula, et al.
Publicado: (2020)

Plant-based dietary approach to stage 3 chronic kidney disease with hyperphosphataemia
por: Campbell, Thomas M, et al.
Publicado: (2019)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Complete heart block in a boy with hyperostosis–hyperphosphataemia syndrome: a case report
por: Hosseini, Zahra, et al.
Publicado: (2019)

Author Correction: Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011)

Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis
por: Tanaka, Akihito, et al.
Publicado: (2023)

Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study
por: Bonanno, Silvia, et al.
Publicado: (2018)

Effectiveness and cost-efficiency of phosphate binders in hemodialysis
por: Fröschl, Barbara, et al.
Publicado: (2009)

Preparation of acid aluminum phosphate solutions for metakaolin phosphate geopolymer binder
por: Yankwa Djobo, Jean Noël, et al.
Publicado: (2021)

ICU-Admission Hyperphosphataemia Is Related to Shock and Tissue Damage, Indicating Injury Severity and Mortality in Polytrauma Patients
por: Rugg, Christopher, et al.
Publicado: (2021)

Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma
por: Iwasaki, Hiroaki
Publicado: (2023)

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2014)

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
por: Paulson, Susan K., et al.
Publicado: (2022)

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients
por: Farrand, Kimberly F, et al.
Publicado: (2014)

Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2023)

Tolerability and efficacy of the intestinal phosphate binder Lantharenol(® )in cats
por: Schmidt, Bernard H, et al.
Publicado: (2012)

The demise of calcium-based phosphate binders—is this appropriate for children?
por: Rees, Lesley, et al.
Publicado: (2014)

Do we need new phosphate binders in dialysis?
por: Cozzolino, Mario, et al.
Publicado: (2020)

Phosphate binders in dialysis: better satisfied than sorry
por: Cozzolino, Mario, et al.
Publicado: (2021)

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability
por: de Francisco, Angel L.M., et al.
Publicado: (2010)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
por: Rodby, Roger A., et al.
Publicado: (2015)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders
por: Bajait, Chaitali S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tbgjp3eps7oh1d5vt2vqepur9b